Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Exclusion Criteria

• •Evidence of distant metastases
• •Regional lymph node involvement
• •Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
• •Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
• •Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol \[DES\]), or surgical castration (orchiectomy)
• •Use of finasteride within 30 days prior to registration; PSA should not be obtained prior to 30 days after stopping finasteride
• •Use of dutasteride within 90 days prior to registration; PSA should not be obtained prior to 90 days after stopping dutasteride
• •Previous or concurrent cytotoxic chemotherapy for prostate cancer
• •Severe, active co-morbidity, defined as follows:
• •Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
• •Transmural myocardial infarction within the last 6 months
• •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• •Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
• •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
• •Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
• •Patients unable to undergo an MRI with contrast